topics / growth hormone
Tagged growth hormone.
- 7/10 · Moderate AOD-9604 A growth-hormone fragment marketed for fat loss. The human trials were small and short, the pivotal obesity study failed, and development was abandoned. Unapproved as a drug everywhere.
- 6/10 · Preliminary CJC-1295 A long-acting GHRH analog that raises GH and IGF-1 in short human trials, but has no clinical-outcome data, is not FDA-approved, and is banned in sport.
- 6/10 · Preliminary GHRP-2: A diagnostic peptide with thin therapeutic evidence GHRP-2 (pralmorelin) provokes a growth hormone pulse. It is an approved diagnostic in Japan, but the human therapeutic and anti-aging evidence is small and old.
- 6/10 · Preliminary GHRP-6: well-mapped pharmacology, unproven benefits An old growth-hormone-releasing peptide that reliably raises GH and appetite in humans, but whose marketed muscle, fat-loss, and disease claims lack solid trials.
- 6/10 · Preliminary Hexarelin: A Potent GH Trigger That Stalled at Early Human Trials A synthetic ghrelin-mimicking peptide that reliably spikes growth hormone in small studies, but was never approved and is banned in sport.
- 6/10 · Preliminary Ipamorelin A selective growth-hormone-releasing peptide with early human safety data but a failed efficacy trial; never approved and banned in sport.
- 7/10 · Moderate MK-677 (Ibutamoren): A Lot of Human Data, Little to Show for It MK-677 reliably raises growth hormone and IGF-1, but disease trials failed and one was stopped for a heart-failure signal. Investigational, never approved.
- 8/10 · Good Sermorelin Sermorelin is a synthetic GHRH fragment that nudges the pituitary to release growth hormone; human data is old and thin, with no modern anti-aging RCTs.
- 10/10 · Established Somatropin (HGH) Recombinant human growth hormone — a protein hormone with strong evidence in true GH deficiency and specific medical conditions, but only small body-composition changes and no proven performance benefit in healthy adults. Non-medical distribution is a federal felony.